Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Concert Pharmaceuticals, Inc. (NASDAQ: CNCE).

Full DD Report for CNCE

You must become a subscriber to view this report.


Recent News from (NASDAQ: CNCE)

Concert Pharmaceuticals to Participate at Upcoming Investor Conferences
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate at the following upcoming investor conferences: The Stifel 2018 Healthcare Conference on November 14, 2018, at 2:00 p.m. ET in New York, NY; The Jefferies 2018 London Healthcare Conference on No...
Source: Business Wire
Date: November, 07 2018 07:00
Concert Pharmaceuticals Presents Preclinical Data on CTP-692, a Novel Drug Candidate for Schizophrenia, Supporting Potential to Improve Safety Profile of D-Serine
Findings Presented at American College of Toxicology 2018 Annual Meeting Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today presented preclinical results that support the potential of CTP-692, the Company’s novel drug candidate for schizophrenia, to improve the safety profi...
Source: Business Wire
Date: November, 05 2018 16:01
Concert Pharmaceuticals, Inc. (CNCE) CEO Roger Tung on Q3 2018 Results - Earnings Call Transcript
Concert Pharmaceuticals, Inc. (CNCE) Q3 2018 Earnings Conference Call November 1, 2018, 08:30 ET Executives Justine Koenigsberg - SVP, Corporate Communications and IR Roger Tung - Co-Founder, CEO, President & Director Marc Becker - CFO James Cassella - Chief Development Off...
Source: SeekingAlpha
Date: November, 01 2018 17:39
Concert Pharmaceuticals, Inc. 2018 Q3 - Results - Earnings Call Slides
The following slide deck was published by Concert Pharmaceuticals, Inc. in conjunction with their 2018 Q3 earnings Read more ...
Source: SeekingAlpha
Date: November, 01 2018 11:43
Concert Pharma misses by $0.11, revenue in-line
Concert Pharma (NASDAQ: CNCE ): Q3 GAAP EPS of -$0.74 misses by $0.11 . More news on: Concert Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: November, 01 2018 07:05
Concert Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Company Update
Conference Call Scheduled Today at 8:30 a.m. ET Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the third quarter of 2018. “This is an exciting time at Concert as we advance multiple pipeline candidates, with our priority directed towar...
Source: Business Wire
Date: November, 01 2018 07:00
Concert Pharmaceuticals to Report Third Quarter 2018 Financial Results on November 1, 2018
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its third quarter 2018 financial results on Thursday, November 1, 2018, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss third quarter fina...
Source: Business Wire
Date: October, 25 2018 07:00
Detailed Research: Economic Perspectives on Graco, Immunomedics, Concert Pharmaceuticals, Macquarie Infrastructure, Systemax, and Service Corporation International - What Drives Growth in Today's Competitive Landscape
NEW YORK, Oct. 12, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Graco Inc. (NYSE:GGG), Immunomedics, Inc. (NASDAQ:IMMU), Concert Pharm...
Source: GlobeNewswire
Date: October, 12 2018 09:15
Concert Pharmaceuticals amends protocol of Phase 2a trial to evaluate 12 mg twice-daily dose cohort of CTP-543
Concert Pharmaceuticals (NASDAQ: CNCE ) announces that it will include an additional cohort of patients in the Phase 2a trial evaluating CTP-543. The protocol amendment provides for additional patients to be enrolled in order to evaluate a 12 mg dose of CTP-543 or placebo twice daily ...
Source: SeekingAlpha
Date: September, 26 2018 07:57
Concert Pharmaceuticals Amends Protocol of Phase 2a Trial to Evaluate 12 mg Twice-Daily Dose Cohort of CTP-543 for the Treatment of Alopecia Areata
Company On Track to Report Topline Data from the 4 mg and 8 mg Twice-Daily Cohorts in Fourth Quarter of 2018 Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will include an additional cohort of patients in the Phase 2a trial evaluating CTP-543. The protocol am...
Source: Business Wire
Date: September, 26 2018 07:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1820.5320.4720.8520.32221,407
2018-05-1720.5320.4720.8520.32221,407
2017-09-1315.1314.9015.1314.8178,800
2017-09-1215.2514.9515.5314.825194,868
2017-09-1115.3614.6715.4514.51111,226

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-117,00539,44217.7603Cover
2018-12-1013,38633,71139.7081Short
2018-12-0768,745127,30753.9994Short
2018-12-0616,17951,35331.5055Cover
2018-12-0415,64040,25438.8533Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CNCE.


About Concert Pharmaceuticals, Inc. (NASDAQ: CNCE)

Logo for Concert Pharmaceuticals, Inc. (NASDAQ: CNCE)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $449,667,584 - 05/11/2018
  • Issue and Outstanding: 23,395,816 - 05/01/2018

 


Recent Filings from (NASDAQ: CNCE)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 03 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: May, 03 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 03 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: April, 13 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: April, 13 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: April, 13 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: April, 13 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 10 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: March, 22 2018
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: March, 07 2018

 

 


Daily Technical Chart for (NASDAQ: CNCE)

Daily Technical Chart for (NASDAQ: CNCE)


Stay tuned for daily updates and more on (NASDAQ: CNCE)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: CNCE)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CNCE is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of CNCE and does not buy, sell, or trade any shares of CNCE. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/